for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Carna Biosciences, Inc.

4572.T

Latest Trade

1,212.00JPY

Change

-17.00(-1.38%)

Volume

53,400

Today's Range

1,205.00

 - 

1,243.00

52 Week Range

1,123.00

 - 

1,736.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
1,229.00
Open
1,243.00
Volume
53,400
3M AVG Volume
2.04
Today's High
1,243.00
Today's Low
1,205.00
52 Week High
1,736.00
52 Week Low
1,123.00
Shares Out (MIL)
12.43
Market Cap (MIL)
15,260.08
Forward P/E
-23.42
Dividend (Yield %)
--

Next Event

Q2 2021 Carna Biosciences Inc Earnings Release

Latest Developments

More

Gilead And Carna Biosciences Announce Research And Development Collaboration

Carna Biosciences says exercise of options

Carna Biosciences to merge with unit

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Carna Biosciences, Inc.

Carna Biosciences, Inc. is a Japan-based company mainly engaged in the drug development support business and the drug development business. The Company operates in two business segments. The Drug Development Support segment is engaged in sales of protein kinase, development of assay, as well as provision of profiling and screening service. The Drug Development segment is engaged in the research and development of kinase inhibitors and other drugs.

Industry

Business Services

Contact Info

KIBC Bldg. 511

5-5-2 Minatojima-Minamimachi

Chuo-ku

KOBE-SHI, HYG

650-0047

Japan

+81.78.3027039

https://www.carnabio.com/

Executive Leadership

Koichiro Yoshino

President, President of Subsidiary, Representative Director

Shinichi Kuwahara

Executive Director

Norio Aikawa

Chief Director of New Drugs Development Support Business, Director of Intellectual Property & Legal Affairs, Director

Masaaki Sawa

Chief Director of Research & Development, Director

Eimi Yamamoto

Chief Director of Business Administration, Director of Accounting, Director

Key Stats

1.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (JPY)

2018

-125.018

2019

76.050

2020

-90.330

2021(E)

-52.400
Price To Earnings (TTM)
--
Price To Sales (TTM)
14.82
Price To Book (MRQ)
4.29
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
10.31
LT Debt To Equity (MRQ)
5.38
Return on Investment (TTM)
-27.69
Return on Equity (TTM)
-24.57

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up